2019 ; Vol.29-9: 1444~1452
|Author||Eunjin Kim, Jihyun Yang, Moon-Hee Sung, Haryoung Poo|
|Place of duty||Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea,College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Republic of Korea|
|Title||Oral Administration of Poly-Gamma-Glutamic Acid Significantly Enhances the Antitumor Effect of HPV16 E7-Expressing Lactobacillus casei in a TC-1 Mouse Model|
J. Microbiol. Biotechnol.2019 ;
|Abstract||The conventional prophylactic vaccines for human papillomavirus (HPV) efficiently prevent
infection with high-risk HPV types, but they do not promote therapeutic effects against
cervical cancer. Previously, we developed HPV16 E7-expressing Lactobacillus casei (L. casei-E7)
as a therapeutic vaccine candidate for cervical cancer, which induces antitumor therapeutic
effects in a TC-1 murine cancer model. To improve the therapeutic effect of L. casei-E7, we
performed co-treatment with poly-gamma-glutamic acid (γ-PGA), a safe and edible
biomaterial naturally secreted by Bacillus subtilis. We investigated their synergistic effect to
improve antitumor efficacy in a murine cancer model. The treatment with γ-PGA did not show
in vitro cytotoxicity against TC-1 tumor cells; however, an enhanced innate immune response
including activation of dendritic cells was observed. Mice co-administered with γ-PGA and
L. casei-E7 showed significantly suppressed growth of TC-1 tumor cells and an increased
survival rate in TC-1 mouse models compared to those of mice vaccinated with L. casei-E7
alone. The administration of γ-PGA markedly enhanced the activation of natural killer (NK)
cells but did not increase the E7-specific cytolytic activity of CD8+ T lymphocytes in mice
vaccinated with L. casei-E7. Overall, our results suggest that oral administration of γ-PGA
induces a synergistic antitumor effect in combination with L. casei-E7.|
|Key_word||Poly-gamma-glutamic acid, adjuvant, Lactobacillus casei, HPV16 E7, cervical cancer, natural killer cells|
Braaten KP, Laufer MR. 2008. Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine. Rev. Obstet. Gynecol. 1: 2-10.
Steller MA. 2003. Human papillomavirus, it's genes and cancer vaccines. Cancer Cell 3: 7-8.
Adachi K, Kawana K, Yokoyama T, Fujii T, Tomio A, Miura S, et al. 2010. Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. Vaccine 28: 2810-2817.
Poo H, Pyo HM, Lee TY, Yoon SW, Lee JS, Kim CJ, et al. 2006. Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice. Int. J. Cancer 119: 1702-1709.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348: 518-527.
Lee JS, Poo H, Han DP, Hong SP, Kim K, Cho MW, et al. 2006. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J. Virol. 80: 4079-4087.
Ault KA. 2007. Long-term efficacy of human papillomavirus vaccination. Gynecol. Oncol. 107: S27-30.
Diniz MO, Lasaro MO, Ertl HC, Ferreira LC. 2010. Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D. Clin. Vaccine Immunol. 17: 1576-1583.
Leggatt GR, Frazer IH. 2007. HPV vaccines: the beginning of the end for cervical cancer. Curr. Opin. Immunol. 19: 232-238.
Narayan S, Choyce A, Linedale R, Saunders NA, Dahler A, Chan E, et al. 2009. Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 T-cell suppression mediated by CD4+CD25+ T cells. Eur. J. Immunol. 39: 481-490.
Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, et al. 2004. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther. 11: 1011-1018.
Zhang H, Zhu J, Zhu X, Cai J, Zhang A, Hong Y, et al. 2012. High-level exogenous glutamic acid-independent production of poly-(gamma-glutamic acid) with organic acid addition in a new isolated Bacillus subtilis C10. Bioresour. Technol. 116: 241-246.
Kim DJ, Kim EJ, Lee TY, Won JN, Sung MH, Poo H. 2013. Combination of poly-gamma-glutamate and cyclophosphamide enhanced antitumor efficacy against tumor growth and metastasis in a murine melanoma model. J. Microbiol. Biotechnol. 23: 1339-1346.
Poo H, Park C, Kwak MS, Choi DY, Hong SP, Lee IH, et al. 2010. New biological functions and applications of highmolecular-mass poly-gamma-glutamic acid. Chem. Biodivers. 7: 1555-1562.
Lee TY, Kim YH, Yoon SW, Choi JC, Yang JM, Kim CJ, et al. 2009. Oral administration of poly-gamma-glutamate induces TLR4- and dendritic cell-dependent antitumor effect. Cancer Immunol. Immunother. 58: 1781-1794.
Kim TW, Lee TY, Bae HC, Hahm JH, Kim YH, Park C, et al. 2007. Oral administration of high molecular mass polygammaglutamate induces NK cell-mediated antitumor immunity. J. Immunol. 179: 775-780.
Alter G, Malenfant JM, Altfeld M. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294: 15-22.
Kim KS, Lee TY, Hong JH, Kim A, Kim SJ, Choi JC, et al. 2013. A single-center, randomized double-blind placebocontrolled study evaluating the effects of poly-gammaglutamate on human NK cell activity after an 8-week oral administration in healthy volunteers. Evid. Based Complement. Alternat. Med. 2013: 635960.
Larsen SK, Gao Y, Basse PH. 2014. NK cells in the tumor microenvironment. Crit. Rev. Oncog. 19: 91-105.
Koo GC, Peppard JR, Hatzfeld A. 1982. Ontogeny of Nk-1+ natural killer cells. I. Promotion of Nk-1+ cells in fetal, baby, and old mice. J. Immunol. 129: 867-871.
Malmberg KJ, Carlsten M, Bjorklund A, Sohlberg E, Bryceson YT, Ljunggren HG. 2017. Natural killer cellmediated immunosurveillance of human cancer. Semin. Immunol. 31: 20-29.
Miller GM, Andres ML, Gridley DS. 2003. NK cell depletion results in accelerated tumor growth and attenuates the antitumor effect of total body irradiation. Int. J. Oncol. 23: 1585-1592.
Indrova M, Simova J, Bieblova J, Bubenik J, Reinis M. 2011. NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours. Oncol. Rep. 25: 281-288.
Noorpisheh Ghadimi S, Farjadian S, Hatam GR, Kalani M, Sarkari B. 2018. Vaccination with live Attenuated L. major and TLR4 Agonist promotes a Th1 immune response and induces protection against L. major infection in BALB/c Mice. Iran J. Immunol. 15: 74-83.
Morefield GL, Hawkins LD, Ishizaka ST, Kissner TL, Ulrich RG. 2007. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Clin. Vaccine Immunol. 14: 1499-1504.
Temizoz B, Kuroda E, Ishii KJ. 2016. Vaccine adjuvants as potential cancer immunotherapeutics. Int. Immunol. 28: 329-338.
Cluff CW. 2010. Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results, pp. 111-123. In Jeannin J-F (ed.), Lipid A in Cancer Therapy, Ed. Springer New York, New York, NY
Lee TY, Kim YH, Lee KS, Kim JK, Lee IH, Yang JM, et al. 2010. Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6expressing Lactobacillus casei in C57BL/6 mice. Cancer Immunol. Immunother. 59: 1727-1737.